The upstream signaling events that lead to EZH2 activation and subsequent cisplatin resistance in lung cancer (mainly NSCLC) possibly include the SETD1A/Wnt/β-catenin feedback loop [116], VEGF/VEGFR2 signaling [89], and AFAP1-AS1 [117]. This evidence concerns the gene EZH2 and non-small cell lung carcinoma.